falsefalse

Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 6

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

Douglas Sborov, MD, discusses how key factors, such as patient eligibility for ASCT, decision-making processes for patients with transplant-eligible NDMM, and the influence of depth of response, including MRD negativity, shape frontline therapy strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients
    EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
    EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy
    EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM
    EP. 5: Looking Ahead and Key Takeaways
    Now Viewing
    EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
    EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7
    EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
    • What factors guide your decision-making for TE patients with NDMM?
    • How do you determine eligibility for ASCT?
    • How does the depth of response (eg, MRD negativity) influence your treatment strategy for these patients?

    Related Content:

    Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients
    Overview of PERSEUS, IsKia, and GMMG-HD7
    Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM
    Looking Ahead and Key Takeaways
    x